mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
Diabetic nephropathy (DN) is among the most lethal complications that occur in type 1 and type 2 diabetics. Podocyte dysfunction is postulated to be a critical event associated with proteinuria and glomerulosclerosis in glomerular diseases including DN. However, molecular mechanisms of podocyte dysfunction in the development of DN are not well understood. Here we have shown that activity of mTOR complex 1 (mTORC1), a kinase that senses nutrient availability, was enhanced in the podocytes of diabetic animals. Further, podocyte-specific mTORC1 activation induced by ablation of an upstream negative regulator (PcKOTsc1) recapitulated many DN features, including podocyte loss, glomerular basement membrane thickening, mesangial expansion, and proteinuria in nondiabetic young and adult mice. Abnormal mTORC1 activation caused mislocalization of slit diaphragm proteins and induced an epithelial-mesenchymal transition-like phenotypic switch with enhanced ER stress in podocytes. Conversely, reduction of ER stress with a chemical chaperone significantly protected against both the podocyte phenotypic switch and podocyte loss in PcKOTsc1 mice. Finally, genetic reduction of podocyte-specific mTORC1 in diabetic animals suppressed the development of DN. These results indicate that mTORC1 activation in podocytes is a critical event in inducing DN and suggest that reduction of podocyte mTORC1 activity is a potential therapeutic strategy to prevent DN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although podocytes have high basal levels of autophagy, high mTORC1 activity is also required for these cells to maintain their function”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ulianich, L., Garbi, C., Treglia, A. S., Punzi, D., Miele, C., Raciti, G. A., Bèguinot, F., Consiglio, E., & Jeso, B. D. (2008) · Journal of Cell Science · doi:10.1242/jcs.017202 · Cited by 114
RetractedTOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Self-citationUpstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Self-citationThe Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911
Self-citationKestilä, M., Lenkkeri, U., Männikkö, M., Lamerdin, J., McCready, P., Putaala, H., Ruotsalainen, V., Morita, T., Nissinen, M., Herva, R., et al. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80057-x · Cited by 1,866
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Boute, N., Gribouval, O., Roselli, S., Benessy, F., Lee, H., Fuchshuber, A., Dahan, K., Gubler, M.-C., Niaudet, P., & Antignac, C. (2000) · Nature Genetics · doi:10.1038/74166 · Cited by 1,444
Research works printed but not linked: 2
- Zhong, Am J Respir Cell Mol Biol.
- Kouraklis, 2006, Oncol Rep., 15, 489
Cited by
Items 401–500 of 544
Biofactors regulating mitochondrial function and dynamics in podocytes and podocytopathies
Hejazian, S. M., Ardalan, M., Khatibi, S. M. H., Saadat, Y. R., Barzegari, A., Gueguen, V., Meddahi‐Pellé, A., Anagnostou, F., Vahed, S. Z., & Pavon‐Djavid, G. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.31110 · Cited by 13
“In the podocyte cell line, HG initially promotes autophagy; however, persistent hyperglycemia decreases podocyte autophagy via insistent activation of the b ‐ arrestin and mTOR pathways (Fang et al., 2013; Inoki et al., 2011; Liu et al., 2016).”
Backgroundvon Rauchhaupt, E., Klaus, M., Ribeiro, A., Honarpisheh, M. M., Li, C., Liu, M., Köhler, P., Adamowicz, K., Schmaderer, C., Lindenmeyer, M. T., et al. (2024) · Cells · doi:10.3390/cells13070637 · Cited by 9
“Autophagy, which is involved in the removal of misfolded proteins, appears to be a crucial pathway for maintaining podocyte health [59,60].”
BackgroundStridh, S., Palm, F., Takahashi, T., Ikegami‐Kawai, M., & Hansell, P. (2015) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2015.1062442 · Cited by 9
“A suggested explanation for the effect is that overactivation of mTORC1 on podocytes, as during hyperglycemia, causes mislocalization of the proteins composing the filtration slits and gives rise to increased endoplasmic reticulum (ER) stress (43).”
BackgroundEffect of liraglutide on endoplasmic reticulum stress in the renal tissue of type 2 diabetic rats
Zhao, X.-Y., Yu, T., Liu, S., Liu, Y.-J., Liu, J., & Qin, J. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i12.611 · Cited by 9
Constitutive activation of the mTOR signaling pathway within the normal glomerulus
McMahon, G. M., Datta, D. B., Bruneau, S., Kann, M., Khalid, M., Ho, J., Seto, T., Kreidberg, J. A., Stillman, I. E., & Briscoe, D. M. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.075 · Cited by 10
“Recent studies using knockout mice indicate that podocyte-specific interruption of mTORC1 function (via deletion of raptor) results in podocyte effacement, histological evidence of glomerular disease and proteinuria [15,34,35].”
BackgroundFan, X., Li, Z., Wang, X., Wang, J., & Hao, Z. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.10.200 · Cited by 9
Self-citationGlucagon receptor activation contributes to the development of kidney injury
Billeschou, A., Johansen, C. D., Galsgaard, K. D., Elmelund, E., Winther‐Sørensen, M., Holst, J. J., Albrechtsen, N. J. W., & Sørensen, C. M. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00088.2024 · Cited by 8
Ketone bodies in renal function and diabetic kidney disease
Mechchate, H. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.109915 · Cited by 8
Approach to Studies on Podocyte Lesions Mediated by Hyperglycemia: A Systematic Review
Silva, J. S., Miguel, C. B., Felipe, A. G. B., Martins, A. L. M. D. S., Miguel, R. B., Carrijo, M. O., Mazurek, L., Araújo, L. S., da Silva, C. A., Goés‐Neto, A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188990 · Cited by 9
TORCing up the Importance of Calcium Signaling
Lavin, P., & Winn, M. P. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011060595 · Cited by 8
Fathoming the Role of mTOR in Diabetes Mellitus and its Complications
Faheem, F., & Sivasubrmanian, S. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666221005123919 · Cited by 8
Tabei, A., Sakairi, T., Hamatani, H., Ohishi, Y., Watanabe, M., Nakasatomi, M., Ikeuchi, H., Kaneko, Y., Kopp, J. B., & Hiromura, K. (2023) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00313.2022 · Cited by 9
Tanaka, Y., Kume, S., Maeda, S., Osawa, N., Takeda, N., Chin‒Kanasaki, M., Isshiki, K., Ugi, S., Oshima, I., Uzu, T., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.145 · Cited by 8
Deletion of IRE1α in podocytes exacerbates diabetic nephropathy in mice
Cybulsky, A. V., Papillon, J., Guillemette, J., Navarro‐Betancourt, J. R., Chung, C.-F., Iwawaki, T., & Fantus, I. G. (2024) · Scientific Reports · doi:10.1038/s41598-024-62599-7 · Cited by 8
“In podocytes, diabetic metabolic changes were shown to perturb the balance between the UPR, autophagy and mTOR signaling 22,41,42 .”
Demir, M. E., Helvacı, Ö., Yıldırım, T., Merhametsiz, Ö., & Sezer, S. (2025) · Clinical Transplantation · doi:10.1111/ctr.70233 · Cited by 7
Chen, Y., Zhao, X., Li, J., Zhang, L., Li, R., Zhang, H., Liao, R., Liu, S., Shi, W., & Liang, X. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9438 · Cited by 9
“GFP signal is sensitive to acidic proteolytic conditions of the lysosome lumen, whereas mRFP is more stable (12)”
Cina, D., Ketela, T., Brown, K. R., Chandrashekhar, M., Mero, P., Li, C., Onay, T., Fu, Y., Han, Z., Saleem, M. A., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00195.2019 · Cited by 7
“Furthermore, a manual cross-referencing of the screen hits to previously described genes involved in podocyte function, either in human disease or animal models, returned 10 podocyte-related genes with various functions, including adhesion and actin regulation [syndecan 1 (SDC1) (17), podocalyxin like (PODXL) (2), col…”
BackgroundWatany, M. M., El‐Horany, H. E., Elhosary, M. M., & Elhadidy, A. A. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00580-8 · Cited by 7
Chhuon, C., Herrera-Marcos, L. V., Zhang, S., Charrière‐Bertrand, C., Jung, V. A., Lipecka, J., Savas, B., Nasser, N., Pawlak, A., Boulmerka, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512124 · Cited by 8
“The aberrant activation of mTORC1 results in negative feedback to PI3K activation [70] and, in podocytes, it leads to cell injury, mimicking a feature of diabetic nephropathy [71,72].”
BackgroundWhy is chronic kidney disease progressive? Evolutionary adaptations and maladaptations
Chevalier, R. L. (2023) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00134.2023 · Cited by 12
A novel therapeutic target for kidney diseases: Lessons learned from starvation response
Yamahara, K., Yasuda‒Yamahara, M., & Kume, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108590 · Cited by 7
Xu, J., Shan, X., Chen, C., Gao, Y., Zou, D., Wang, X., Wang, T., & Shi, Y. (2022) · Journal of Diabetes Research · doi:10.1155/2022/1610416 · Cited by 6
“It has been reported that the viability of podocytes is related to the down-regulation of extracellular high glucose-dependent autophagy [31].”
BackgroundTuberous Sclerosis Complex Kidney Lesion Pathogenesis: A Developmental Perspective
Pietrobon, A., & Stanford, W. L. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000146 · Cited by 6
Vidigal, A. C., de Lucena, D. D., Beyerstedt, S., & Rangel, É. B. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2243808 · Cited by 6
Elliott, J., & Oyama, M. A. (2024) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.13472 · Cited by 8
Dasare, A. P., Gondaliya, P., Srivastava, A., & Kalia, K. (2019) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-019-00409-y · Cited by 7
Up-regulated mTOR pathway indicates active disease in both human native and transplant kidneys.
Li, W., & Zhang, P. L. (2013) · PubMed · Cited by 6
Ren, X., Liu, G., Wang, Y., Zhang, W., Xue, F., Li, R., & Yu, W. (2017) · Pharmacology · doi:10.1159/000455874 · Cited by 6
Pallet, N. (2017) · médecine/sciences · doi:10.1051/medsci/20173303014 · Cited by 6
Grahammer, F., Benzing, T. R., & Huber, T. B. (2015) · Kidney International · doi:10.1038/ki.2015.5 · Cited by 6
Self-citationThe sclerosing glomerulus in mice and man
Mondini, A., Messa, P., & Rastaldi, M. P. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000444817.95496.40 · Cited by 6
“For example, in diabetic nephropathy, mTOR hyperactivity seems to be responsible for podocyte damage, glomerulosclerosis, and disease progression [28,29].”
BackgroundSelf-citationÁlamo-Martínez, J. M., Olivares, C., Barrera, L., Gómez, L. M. M., Suárez, G., Bellido, C. B., Serrano, J., Muntané, J., Ruiz, F. J. P., & Gómez‐Bravo, M. Á. (2015) · World Journal of Transplantation · doi:10.5500/wjt.v5.i1.19 · Cited by 5
Ogawa, S., Ishimura, T., Miyake, H., & Fujisawa, M. (2017) · International Journal of Urology · doi:10.1111/iju.13287 · Cited by 5
Transcriptome analysis of primary podocytes reveals novel calcium regulated regulatory networks
Struk, T., Nair, V., Eichinger, F. H., Kretzler, M., Wedlich‐Söldner, R., Bayraktar, S., & Pavenstädt, H. (2020) · The FASEB Journal · doi:10.1096/fj.201902493rr · Cited by 5
Self-citationSugahara, M., Tanaka, T., Inagi, R., & Nangaku, M. (2017) · Springer eBooks · doi:10.1007/978-981-10-4376-5_1 · Cited by 5
Liu, X., Mao, Z., Yuan, M., Li, L., Tan, Y. C. R. S., Qu, Z., Chen, M., & Yu, F. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-000896 · Cited by 5
Rapamycin treatment induces tubular proteinuria: role of megalin-mediated protein reabsorption
Peres, R. A. S., Peruchetti, D. B., Silva-Aguiar, R. P., Teixeira¹, D. E., Gomes, C. P., Takiya, C. M., Pinheiro, A. A. S., & Caruso‐Neves, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1194816 · Cited by 6
“It is well known that during the development of DKD, there is overactivation of mTORC1 in glomerular and tubular structures involved with kidney damage (Gödel et al., 2011; Inoki et al., 2011; Kogot-Levin et al., 2020).”
BackgroundProtective effects of low-dose rapamycin combined with valsartan on podocytes of diabetic rats.
Zhang, J. C., Hu, X., Wang, S., Zhang, Y., & Yang, H. (2015) · Europe PMC (PubMed Central) · Cited by 5
Yasunaga, M., Kajiya, H., Toshimitsu, T., Nakashima, H., Tamaoki, S., Ishikawa, H. T., Maeda, H., & Ohno, J. (2019) · Journal of Hard Tissue Biology · doi:10.2485/jhtb.28.63 · Cited by 6
Yu, S., Ren, Q., Chen, J., Huang, J., & Liang, R. (2022) · European Journal of Inflammation · doi:10.1177/1721727x221081732 · Cited by 5
“The PI3K/AKT pathway can regulate podocyte autophagy, damage podocytes, and destroy the stability of the SD complex.(11) Studies have confirmed that the PI3K/Akt pathway participates in the development of diabetic nephropathy and septic kidney injury by regulating podocyte autophagy to induce podocyte damage.”
BackgroundSeveral reasons for the development of proteinuria in nephrotic syndrome
Zverev, Y. F., & Rykunova, A. Y. (2020) · Nephrology (Saint-Petersburg) · doi:10.36485/1561-6274-2020-24-1-9-21 · Cited by 4
“Оказалось, что образующийся на основе mTOR комплекс mTORC1 (mTOR-GβL-Раптор) играет ключевую регуляторную роль при повреждении подоцитов на модели ДН у мышей [39].”
Tavakolidakhrabadi, N., Ding, W. Y., Welsh, G. I., & Saleem, M. A. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf332 · Cited by 4
“The mechanistic target of rapamycin ( MTOR) pathway, for instance, is central to regulating cell growth, metabolism, and autophagy, and dysregulated mTOR signalling can lead to cytoskeletal abnormalities that favour foot-process effacement [32 , 33 ].”
Liu, T., & Li, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1599097 · Cited by 4
“Additionally, it effectively inhibits the mechanistic target of rapamycin (mTOR) pathway associated with renal injury in mammals (Inoki et al., 2011; Liu et al., 2010; Sakaguchi et al., 2006).”
Lin, J., Lin, Y., Li, X., He, F., Gao, Q., Wang, Y., Huang, Z., & Xiong, F. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s446752 · Cited by 4
“14 These findings emphasize the critical role of anoikis in DKD pathology.”
BackgroundThe role and mechanism of TSC in kidney diseases: a literature review
Luo, Q., Zheng, X., Xu, Y., Fan, Y., Zhang, H., Li, T., Zhang, X., Peng, L., Jiang, X., & Dai, H. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04260-7 · Cited by 5
Old friends form alliance against podocytes
Simons, M., & Huber, T. B. (2011) · Kidney International · doi:10.1038/ki.2011.298 · Cited by 4
Self-citationHigh glucose couples DJ-1 with PTEN to activate PDGFRβ for renal proximal tubular cell injury
Das, F., Ghosh‐Choudhury, N., Kasinath, B. S., Sharma, K., & Choudhury, G. G. (2025) · PLoS ONE · doi:10.1371/journal.pone.0311828 · Cited by 5
mTOR in Diabetic Nephropathy and Retinopathy
Fernandes, R., & Reis, F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00001-3 · Cited by 4
DEPTOR Polymorphisms Influence Late Complications in Type 2 Diabetes Patients
Klen, J., Goričar, K., Horvat, S., Stojan, J., & Dolžan, V. (2019) · Pharmacogenomics · doi:10.2217/pgs-2019-0058 · Cited by 4
Miesen, L., Eymael, J., Sharma, S., Loeven, M. A., Willemsen, B. K., Bakker, M. A. H., Mooren, F., Meyer‐Schwesinger, C., Dijkman, H. B. P. M., Wetzels, J. F. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65352-y · Cited by 6
Yan, Y., Yu, S., & Fan, Y. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/161733 · Cited by 4
Farooqui, Z., & Banday, A. A. (2023) · Peptides · doi:10.1016/j.peptides.2023.171136 · Cited by 4
Could Autophagic Exhaustion Be a Final Common Pathway for Podocytopathy in FSGS?
Venkatachalam, M. A. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014090919 · Cited by 4
Zaini, L. M., Kartasasmita, A., Gondhowiardjo, T. D., Syukri, M., & Lesmana, R. (2022) · Expert Review of Ophthalmology · doi:10.1080/17469899.2022.2111302 · Cited by 3
“indicates that mTOR inhibition may suppress podocyte injury and delay the progression of diabetic nephropathy [51].”
BackgroundThe histologic disorders and underlying mechanisms of podocytes during diabetes
Qian, S., Su, H., & Zhang, C. (2022) · Diabetic Nephropathy · doi:10.2478/dine-2022-0021 · Cited by 3
Das, F., Ghosh‐Choudhury, N., Kasinath, B. S., Sharma, K., & Choudhury, G. G. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114116 · Cited by 3
Zhang, J., Cheng, L. L., Jiang, S., & Zhu, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-99395-w · Cited by 3
Özel, C., Reitmeier, K., Kieckhöfer, E., Abualia, K., Nguyen-Minh, D., Matin, M., Hagmann, H., Coward, R. J., Brähler, S., Antczak, P., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202502934r · Cited by 3
“Pharmacological inhibition of mTORC1 with rapamycin has shown promise in restoring signaling balance and reducing podocyte apoptosis, particularly under high-glucose conditions [17].”
Dietary methionine mitigates immune-mediated damage by enhancing renal clearance of cytokines
Troha, K., Kambhampati, S., Insenga, A., Metallo, C. M., & Ayres, J. S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2025.12.011 · Cited by 5
Naik, A. S., Alakwaa, F., Nair, V., McCown, P. J., Schaub, J. A., Otto, E. A., Menon, R., Annese, F., Choi, Y. J., Hampson, H. E., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci198545 · Cited by 3
“Notably, DNA methylation, for example, via increased DNA methyltransferases (DNMT1) leads to hypermethylation of negative regulators of mTOR, resulting in mTORC1 pathway activation, leading to increased inflammation in DKD. Targeting DNMT1 or reversing the methylation was shown to reduce immune cell–driven inflammatio…”
InfluentialSelf-citationEpidermal growth factor receptor signaling and the progression of diabetic nephropathy
Koya, D. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12317 · Cited by 3
“Briefly, Inoki et al.(13) found that binding immunoglobu-”
BackgroundMolecular Basis of Kidney Disease
Tan, R. J., Bastacky, S., & Liu, Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802761-5.00024-9 · Cited by 3
Renal Disease in Obesity, Metabolic Syndrome and Diabesity
Porrini, E., Navarro-Díaz, M., Rodríguez-Rodríguez, R., & SALIDO, E. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_5 · Cited by 3
Tensin 2-deficient nephropathy: mechanosensitive nephropathy, genetic susceptibility
Sasaki, H., & Sasaki, N. (2022) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.22-0031 · Cited by 3
“This mTORC1 activation is associated with podocyte dysfunction in DN [51, 52].”
BackgroundSingh, A. P., Kalil, R. S., & Weir, M. R. (2023) · American Journal of Nephrology · doi:10.1159/000530296 · Cited by 4
Tensins in Kidney Function and Diseases
Huang, C., & Lo, S. H. (2023) · Life · doi:10.3390/life13061244 · Cited by 3
“Interestingly, it has been repor ed that TNS2 regulat s podocyte hypertrophy through mTORC1 activation [6], which is k own to impair podocyte f nction in diabetic nephropathy [65].”
BackgroundSoypaçacı, Z., Çakmak, Ö., Çakalağoğlu, F., Gerçik, Ö., Ertekin, İ., Üzüm, A., Ersoy, R., & Akar, S. (2019) · Renal Failure · doi:10.1080/0886022x.2019.1667829 · Cited by 3
“In diabetic nephropathy, substantial mTORC1 activation was detected at early stages leading to an unbalanced cell hypertrophy, de-differentiation, podocyte detachment, and progressive glomerulosclerosis [24].”
BackgroundProteomic Study of Low-Birth-Weight Nephropathy in Rats
Imasawa, T., Claverol, S., Lacombe, D., Amoêdo, N. D., & Rossignol, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910294 · Cited by 3
Lin, Y., Sayols-Baixeras, S., Graells, T., Dekkers, K. F., Baldanzi, G., Nguyen, D. T., Larsson, A. O., Feldreich, T., Nielsen, N., Eklund, A. C., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf453 · Cited by 3
“In experimental studies, imidazole propionate has been shown to activate mTORC1 via impaired insulin signaling, which can lead to podocyte hypertrophy, mesangial expansion, glomerular basement membrane thickening, foot process effacement, podocyte loss, and albuminuria in mice (15, 16).”
Koçak, A., Aydin, E., Gündüz, M. K., Kaymak, G., Aydın, B., & Değer, A. N. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115661 · Cited by 2
Morin, G., Isnard, P., & Canaud, G. (2025) · Kidney International · doi:10.1016/j.kint.2025.08.041 · Cited by 2
Ma, P., (18005), Y. G., Wang, H., Jiang, X., Tang, Y., Gong, M., Gong, J., Dong, H., & Su, H. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108283 · Cited by 2
Akilesh, S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.05403-4 · Cited by 3
Cannabinoid Signaling in the Diabetic Proximal Tubule: Of Mice and Men
Naik, A. S., & Brosius, F. C. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.09.004 · Cited by 2
Mechanisms of Diabetic Nephropathy in Humans and Experimental Animals
Khoury, C. C., Chen, S., & Ziyadeh, F. N. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_9 · Cited by 2
The CLCA1/TMEM16A/Cl– current axis associates with H2S deficiency in diabetic kidney injury
Lee, H. J., Sun, Y., Das, F., Ju, W., Nair, V., Kevil, C. G., Varadarajan, S., Zhang, G., Choudhury, G. G., Singh, B. B., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174848 · Cited by 2
“We explored the mechanism underlying augmented Tmem16A mRNA translation. mTORC1 activates mRNA translation in diabetic kidney injury (30, 37, 46, 47).”
Self-citationPathogenesis of diabetic microvascular complications
Forbes, J. M., & Harcourt, B. E. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch60 · Cited by 3
Aging Kidney: Modern Perspectives for an ‘Old’ Problem
Grosjean, F., Vlassara, H., & Striker, G. E. (2011) · Aging Health · doi:10.2217/ahe.11.63 · Cited by 2
Regulation of Renal Hyaluronan in Water Handling : Studies in vivo and in vitro
Stridh, S. (2013) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 2
CIN85: Implications for the Development of Proteinuria in Diabetic Nephropathy
Nagai, K., & Doi, T. (2016) · Diabetes · doi:10.2337/dbi16-0051 · Cited by 1
“Several molecules and signal pathways in podocytes, such as b-arrestin2 (18) and mTORC1 pathway (19), were shown to be involved in the development of DN.”
BackgroundAl-Diab, O., Suenkel, C., Blanc, E., Catar, R. A., Ashraf, M., Zhao, H., Wang, P., Rinschen, M. M., Fritsche‐Guenther, R., Grahammer, F., et al. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00647-7 · Cited by 1
“…the 3 month treat-ment period for the induction of longevity effects and the 25 weeks of treatment with relevant functional and structural effects [133] might be considered for conception of such proof of concept studies for the effectiveness of time-restricted administration of rapamycin in…”
BackgroundSelf-citationLiu, F., Xu, Z., Chen, G., Xu, X., Cao, H., & Chen, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1445550 · Cited by 1
Mitochondrial integrity modulates mTOR signaling and podocyte function
Özel, C., Abualia, K., Nguyen-Minh, D., Matin, M., Unnersjö‐Jess, D., Höhne, M., Bloch, W., Hagmann, H., Coward, R. J., Brähler, S., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114279 · Cited by 1
Rooney, F., Allamargot, C., Williquett, J., & Sun, H. L. (2025) · Microscopy and Microanalysis · doi:10.1093/mam/ozaf122 · Cited by 1
“Historically, TEM has been used to quantify podocyte foot process width (FPW) as an ultrastructural marker in both human biopsies and animal models of DN (Inoki et al., 2011; Li et al., 2025 ).”
Srivastava, S. P., Kopasz-Gemmen, O., Kunamneni, A., Thurman, A., Yoshida, S., Ozkan, E. E., Swaroop, V., Nanwani, R., Arora, A., Joshi, A., et al. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03078-y · Cited by 2
“Streptozotocin was purchased from Sigma.”
Self-citationGenetic aspects of familial focal segmental glomerulosclerosis
Agrawal, S., Prakash, S., & Sharma, R. K. (2014) · Clinical Queries Nephrology · doi:10.1016/j.cqn.2014.06.001 · Cited by 1
Joo, D. J., Yang, C. W., Jeong, H. J., Lim, B. J., Huh, K. H., Chung, B. H., Choi, Y. J., Kang, S., & Kim, Y. S. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.8.1069 · Cited by 1
“The complete inhibition of mTORC1 activity with sirolimus treatment may worsen podocyte function and fail to yield a better clinical outcome because the PI3K-mTORC1 function in podocytes is essential for the maintenance of podocyte function and the integrity of the filtration barrier (37).”
BackgroundThe Podocyte in Diabetic Nephropathy: Recent Advances
Welsh, G. I., & Coward, R. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_11 · Cited by 1
Endoplasmic Reticulum Stress Signalling During Development
Dominicus, C. S., Patel, V., Chambers, J. E., Malzer, E., & Marciniak, S. J. (2019) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-05067-2_2 · Cited by 1
Sirtuins in diabetes mellitus and diabetic kidney disease
Türkmen, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822467-0.00014-0 · Cited by 1
Tanaka, R., Imamura, R., Matsumura, S., Fukae, S., Taniguchi, A., Nakazawa, S., Yamanaka, K., Namba‐Hamano, T., Kakuta, Y., Takao, T., et al. (2024) · The Nephron journals/Nephron journals · doi:10.1159/000535877 · Cited by 1
The Role of Sirtuins in Diabetic Nephropathy: A Comprehensive Review
Wal, P., Tarannum, T., Baldaniya, L. H., Kaur, K., Singh, P., Aziz, N., Singh, K., & Gasmi, A. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037340795241202044932 · Cited by 1
Role of the podocyte signal-transduction systems in the pathogenesis of diabetic nephropathy
Kaburagi, Y., & Unoki‐Kubota, H. (2011) · Diabetology International · doi:10.1007/s13340-011-0053-8
“[12] recently generated mice with podocyte-specific ablation of an upstream negative regulator of mTORC1, TSC1, to analyze the effects of constitutive mTORC1 activation on glomerular function.”
BackgroundFougeray, S. (2012) · theses.fr (ABES) · doi:10.70675/f71bbcabz6bacz4424z9870z8589cbef3e54 · Cited by 3
The Role of Podocytes in Renal Diseases
Asanuma, K., Hidaka, T., & Tomino, Y. (2012) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.101.1092
Energy and Mammalian Target of Rapamycin Complex 1 (mTORC1) in Minimal Change Nephrotic Syndrome
Yan, K. (2015) · Springer eBooks · doi:10.1007/978-4-431-55270-3_5
Drug-induced and toxic glomerulopathies
Woywodt, A., & Chiu, D. Y. Y. (2015) · Oxford University Press eBooks · doi:10.1093/med/9780199592548.003.0082
The glomerulus and the concept of glomerulonephritis
Woywodt, A., & Chiu, D. Y. Y. (2015) · Oxford University Press eBooks · doi:10.1093/med/9780199592548.003.0042
mTOR: Pumping Nutrients into Tubules
Inoki, K. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016080924
Self-citationRahman, H. (2012) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-528
Metadata
- Authors
- Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., Kwiatkowski, D. J., Rastaldi, M. P., Huber, T. B., Kretzler, M., Holzman, L. B., Wiggins, R. C., & Guan, K.-L.
- Affiliations
- University of Michigan (US)
- Life Sciences Institute (SG)
- University of Basel (CH)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- University of Freiburg (DE)
- University Medical Center Freiburg (DE)
- University of California San Diego (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-06-01
- Volume
- 121
- Issue
- 6
- Pages
- 2181-2196
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3104745
- OpenAlex
- W2033798110
- Cited by
- 538
- References
- 77
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 23 · 2023: 36 · 2022: 33 · 2021: 22 · 2020: 48 · 2019: 43 · 2018: 39 · 2017: 39 · 2016: 39 · 2015: 35 · 2014: 44 · 2013: 45 · 2012: 36
- FWCI
- 35.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- edoc (University of Basel) (acceptedVersion)
- edoc (University of Basel)
- Funders
- National Institutes of Health (5r01dk083491-09, DK083491)
- National Cancer Institute (R01CA108941)
- National Institute of General Medical Sciences (R01GM051586, GM051586)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK083491, DK-083491, R01DK124709)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Oncology › Renal and related cancers
- Keywords
- diabetic nephropathy, mTORC1, podocytes, podocyte loss, proteinuria, glomerulosclerosis, endoplasmic reticulum stress, epithelial-mesenchymal transition, slit diaphragm proteins, TSC1, chemical chaperones, mesangial expansion, glomerular basement membrane thickening
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Regulatory-Associated Protein of mTOR, Tuberous Sclerosis Complex 1 Protein, Animals, Carrier Proteins, Cell Differentiation, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Disease Models, Animal, Endoplasmic Reticulum, Enzyme Activation, Glomerular Mesangium, Male, Membrane Proteins, Mice, Inbred C57BL, Mice, Mutant Strains, Phosphorylation, Protein Processing, Post-Translational, Proteins, Mice, Knockout, Ribosomal Protein S6 Kinases, Sirolimus, Tumor Suppressor Proteins, Multiprotein Complexes, Adaptor Proteins, Signal Transducing, Podocytes, Glomerular Basement Membrane, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.